Meyka Pro banner
Sinopharm Group Co. Ltd.

Sinopharm Group Co. Ltd. (1099.HK) Stock Competitors & Peer Comparison

See (1099.HK) competitors and their performances in Stock Market.

1099.HKHKSE
HealthcareMedical - Distribution
HK$17.32
HK$0.30(1.70%)
Hong Kong Market is Open · 09:59

Peer Comparison Table: Medical - Distribution Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1099.HKHK$17.32-1.70%54B6.87HK$2.52+4.56%
2607.HKHK$12.00-0.50%69.6B6.26HK$1.92+4.47%
2192.HKHK$7.50-0.66%5.5B15.10HK$0.50+3.87%
2656.HKHK$10.05+3.29%3.5B-35.89-HK$0.28N/A
2427.HKHK$2.38+9.17%2.3B-79.33-HK$0.03N/A
2290.HKHK$3.71-0.80%1.9B0.02HK$170.43N/A
1931.HKHK$0.64+0.00%1B3.27HK$0.20N/A
2289.HKHK$6.80-6.85%734.4M12.89HK$0.53+5.05%
9955.HKHK$0.52+0.00%335.8M-0.95-HK$0.55N/A
1298.HKHK$1.10-8.33%303M80.59HK$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1099.HK vs 2607.HK Comparison July 2026

1099.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1099.HK stands at 54B. In comparison, 2607.HK has a market cap of 69.6B. Regarding current trading prices, 1099.HK is priced at HK$17.32, while 2607.HK trades at HK$12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1099.HK currently has a P/E ratio of 6.87, whereas 2607.HK's P/E ratio is 6.26. In terms of profitability, 1099.HK's ROE is +0.09%, compared to 2607.HK's ROE of +0.08%. Regarding short-term risk, 1099.HK is more volatile compared to 2607.HK. This indicates potentially higher risk in terms of short-term price fluctuations for 1099.HK.Check 2607.HK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions